移至主內容
Taiwan Novartis Pro | 台灣諾華醫學資訊平台
登入
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Navigation
Navigation

Navigation

  • Cosentyx® (secukinumab)
    • COSENTYX JIA健保給付規定
    • Cosentyx is the first and the only biological treatment indicated for ERA in pediatric patients in the Taiwan
    • Cosentyx® 可顯著且持續改善難治部位 PsO
    • Cosentyx® 從皮膚到關節,展現多面向疾病控制
    • HS健保事審
    • IL-17i 顯著降低 PsO 病人發展至 PsA 風險展現明確且一致的預防優勢
    • STEP in early with SEC for breaking the cycle of HS with biologic therapy
    • [JIA on AIR] 台大楊曜旭醫師 - JIA 治療的關鍵時刻: 我們如何改變孩子的未來
    • [JIA on AIR] 台大楊曜旭醫師 - JIA分型治療大不同 接骨點炎型的臨床挑戰
    • [JIA on AIR] 林口長庚姚宗杰醫師 - 孩子關節痛,不只是長高的代價!
    • 皮膚症狀快速改善
  • Xolair® (omalizumab)

Cosentyx is the first and the only biological treatment indicated for ERA in pediatric patients in the Taiwan

  • 列印
  • PDF
FA-11403020_20270415
  • 列印
  • PDF
FA-11403020_20270415

台灣諾華
本網站僅提供醫療專業人員使用

  • 探索網站
  • 實用連結
  • 使用條款
  • 隱私聲明

© 2026 Novartis

This website is only intended for healthcare professionals with prescribing authority.

I am a Healthcare Professional.
I am not a Healthcare Professional.

and agree to the Data Privacy and Term of Use policy of this website

The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

Login